1.64Open1.50Pre Close52 Volume231 Open Interest6.00Strike Price8.47KTurnover79.18%IV0.27%PremiumDec 20, 2024Expiry Date1.33Intrinsic Value100Multiplier16DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.9040Delta0.1405Gamma5.24Leverage Ratio-0.0071Theta0.0023Rho4.73Eff Leverage0.0026Vega
BioCryst Pharmaceuticals Stock Discussion
BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.81%)
Larger Image: tradingview.com...
$BioCryst Pharmaceuticals (BCRX.US)$
Benzinga· 3 mins ago
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reduc...
Just
U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile
Jefferies analysts cited 10 possible policies that Tr...
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
No comment yet